PP
BLCM

PDT Partners’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

PDT Partners’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,702
Closed -$393K – 1040
2015
Q3 		$393K Buy
+2,702
New +$496K 0.01% 974

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PDT Partners's BLCM Position: Q4 2015 in Review

PDT Partners sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2015, closing a stake of 2,702 shares — an estimated $393K sold.

PDT Partners first reported a position in BLCM in Q3 2015 and held it in 1 quarter. The position peaked at $393K in Q3 2015. 81 funds tracked by Wall St. Rank hold BLCM as of Q4 2015.

  • PDT Partners reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • PDT Partners sold 2,702 Bellicum Pharmaceuticals, Inc. shares in Q4 2015, an estimated $393K.
  • PDT Partners first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • PDT Partners's Bellicum Pharmaceuticals, Inc. position peaked at $393K in Q3 2015.
  • 81 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2015.

Based on PDT Partners's 13F filing for Q4 2015, filed 16 Feb 2016.